Synthetic biology and QA/QC testing market for cannabinoids
Summary
The passage is a commercial market analysis describing production methods and testing opportunities for CBD. It mentions no high‑profile officials, agencies, or controversial financial flows, and prov Synthetic biology can produce cannabinoids via fermentation. QA/QC testing standards for CBD are currently fragmented across states. Life‑science instrument makers (Agilent, Danaher, PerkinElmer, Shi
This document is from the House Oversight Committee Releases.
View Source CollectionTags
Related Documents (6)
Cannabis Investment Report – Market Overview and Funding Landscape (Dec 2017)
The document is a generic industry analysis with no mention of high‑profile political figures, intelligence agencies, or controversial financial flows. It provides market commentary and fundraising to Reports $2.0 billion raised by cannabis‑related companies in 2017. Highlights Canadian exchanges (TSX, TSXV, CSE) as primary venues for cannabis listings. Notes ongoing U.S. federal prohibition limit
Ackrell Capital Cannabis Investment Report (Dec 2017) – Canadian Stock Market Comparison
The document is a routine market analysis with no mention of high‑profile individuals, government agencies, or controversial transactions. It provides generic data on exchange listings and financial c Shows that >10% of Canadian Securities Exchange listings are cannabis‑related. Compares market size and median company values across TSX, TSXV, and CSE. Outlines listing and governance requirements f
Capital Markets Overview for Public Cannabis Companies (2017)
The passage provides aggregate financing data and market listings for cannabis‑related public companies, but it contains no specific allegations, transactions, or individuals that suggest misconduct o US cannabis firms raised $1.35 bn across 78 deals in the 12‑month period ending Sep 30 2017. Canada contributed $1.056 bn of that capital; Australia $26 m. Four cannabis firms traded on Nasdaq, one R
Cronos Group partners with Ginkgo Bioworks to develop cultured cannabinoids valued up to $122M
The passage details a commercial biotech partnership between a Canadian cannabis firm and a synthetic biology startup. It provides financial terms and milestones but does not implicate high‑ranking po Agreement announced September 2018 between Cronos Group and Ginkgo Bioworks. Total deal value up to $122 million, including $22 million R&D funding and up to $100 million in Cro Ginkgo to engineer ye
Cannabis industry company directory from a 2017 investment report
The passage is a simple product and company listing from a 2017 investment report with no mention of influential political figures, financial flows, or misconduct. It provides no actionable leads for Lists vaporizer manufacturers Vapexhale (San Francisco) and Vuber (Seattle). Lists cannabis product companies VCC Brands (Los Angeles) and Wana Brands (Boulder). Includes website URLs and product typ
Cannabis Industry Segmentation Report Highlights Production Opportunities and Challenges
The passage is a generic market analysis without any specific names, transactions, or allegations linking powerful actors to misconduct. It offers no actionable investigative leads. Identifies specialized production services and extraction as high‑margin opportunities. Notes demand for energy‑efficient integrated cultivation systems. Suggests a potential certification market for laboratory testing
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.